Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | RXRB | P28702 | 2/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 2/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17811497 | 0.92 | NR1H2 (0.37) | NR1H2NR1H3PDE4APDE4BPDE4C | |
| SCHEMBL17811491 | 0.81 | ACHE (0.42) | NR1H2NR1H3PDE4APDE4BPDE4C | |
| SCHEMBL20306677 | 0.74 | PTGS2 (0.37) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL17815539 | 0.74 | SLC6A4 (0.39) | PDE4APDE4BPDE4CPDE4DRXRA | |
| SCHEMBL20306696 | 0.74 | ALDH1A1 (0.46) | — | |
| SCHEMBL17811494 | 0.74 | — | — | |
| SCHEMBL17811498 | 0.72 | ACHE (0.39) | NR1H2NR1H3PDE4APDE4BPDE4C | |
| SCHEMBL17811469 | 0.70 | RAB9A (0.48) | PDE4APDE4BPDE4CPDE4DSMN1; SMN2 | |
| SCHEMBL17811495 | 0.70 | NR1H2 (0.38) | NR1H2NR1H3PDE4APDE4BPDE4C | |
| SCHEMBL17815473 | 0.69 | MAOA (0.44) | SMN1; SMN2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | TRINSEO EUROPE GMBH (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20160159956-A1 | Polymerisation Initiators | TRINSEO EUROPE GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | ELOVL5, ELOVL3, ELOVL1 | NR1H2 3711/4885NR1H3 3601/4885PDE4A 3472/4885 |
| US-20160159956-A1 | Polymerisation Initiators | ELOVL5, ELOVL3, ELOVL1 | NR1H2 3711/4885NR1H3 3601/4885PDE4A 3472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.